Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9011252 | 0.85 | MAPK1 (0.71) | MAPK1KMT2AMEN1NPC1RAB9A | |
| SCHEMBL8726926 | 0.77 | ADRB2 (0.47) | KMT2ASMN1; SMN2GAAMAPTLMNA | |
| SCHEMBL8728521 | 0.76 | CA12 (0.49) | KMT2AMEN1SMN1; SMN2MAPTLMNA | |
| SCHEMBL9404972 | 0.75 | MAPK1 (0.57) | MAPK1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL8728512 | 0.74 | ADRB2 (0.46) | KMT2AMEN1SMN1; SMN2MAPTLMNA | |
| SCHEMBL8510531 | 0.74 | CHRM5 (0.38) | KMT2ANPC1SMN1; SMN2GAAL3MBTL1 | |
| SCHEMBL9011269 | 0.74 | MAPK1 (0.76) | MAPK1KMT2AMEN1NPC1RAB9A | |
| SCHEMBL9404946 | 0.74 | MAPK1 (0.56) | MAPK1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL9404951 | 0.74 | MAPK1 (0.56) | MAPK1KMT2AMEN1NPC1RAB9A | |
| SCHEMBL21510393 | 0.73 | KDM4E (0.52) | SMN1; SMN2HSD17B10MAPTLMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0335545-B2 | Pharmaceutical formulations for parenteral use | UNIV FLORIDA (US) | 1998-09-23 | — | — | EP | disclosed |
| EP-0327766-B1 | Redox systems for brain-targeted drug delivery | UNIV FLORIDA (US) | 1998-04-08 | — | — | EP | disclosed |
| US-5024998-A | Administering in aqueous solution with cyclodextrin derivative | UNIVERSITY OF FLORIDA (US) | 1991-06-18 | — | — | US | disclosed |
| US-5017566-A | Redox systems for brain-targeted drug delivery | UNIVERSITY OF FLORIDA (US) | 1991-05-21 | — | — | US | disclosed |
| US-5002935-A | Inclusion Complexing Hydroxypropylcyclodextrin with a Dihydropyridine-substituted Drug | UNIVERSITY OF FLORIDA (US) | 1991-03-26 | — | — | US | disclosed |
| US-4983586-A | Decreasing precipitation at injection site or in lungs or other organs by combining with hydroxypropyl-beta-cyclodextrin | UNIVERSITY OF FLORIDA (US) | 1991-01-08 | — | — | US | disclosed |
| EP-0335545-A2 | Pharmaceutical formulations for parenteral use | UNIVERSITY OF FLORIDA (US) | 1989-10-04 | — | — | EP | disclosed |
| EP-0327766-A2 | Redox systems for brain-targeted drug delivery | UNIVERSITY OF FLORIDA (US) | 1989-08-16 | — | — | EP | disclosed |